Prostate Cancer : Episode 2

Video

Episode 2 - Immunotherapy in CRPC

During this segment, David Crawford, MD, discusses immunotherapy’s role in castration-resistant prostate cancer (CRPC), and explains how the US Food and Drug Administration’s approval of sipuleucel-T has led to a paradigm shift in the way that CRPC is treated.

Dr Crawford explains the unique capabilities of immunotherapy for advanced disease when compared to conventional treatment options such as cytotoxic chemotherapy.

Additionally, David Quinn, MD, discusses hormonal therapy agents, the key clinical trials that have tested these treatment options, and explains how the trials have demonstrated improved outcomes in CRPC.


Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Sundar Jagannath
Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS
Mehmet Oz, MD, MBA
Ayodeji Adegunsoye, MD, PhD, MSc
Marilyn Glassberg, MD
Dr Caroline Vovan
Interview with Miriam Freimer, MD, The Ohio State University Wexner Medical Center
Merrill H. Stewart, MD
Rachel Rohaidy, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo